AbCellera to Participate at Upcoming Investor Conferences in March

Business Wire

12 Feb

VANCOUVER, British Columbia, February 11, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

45th Annual TD Cowen Health Care Conference, March 3-5
KeyBanc Capital Markets Healthcare Forum, March 18-19

Visit AbCellera's Investor Relations website for additional information.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211013862/en/

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(604)724-1242
Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510357147"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510357147\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2510357147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2510357147","market":"us","top_or_hot":-1,"title":"AbCellera to Participate at Upcoming Investor Conferences in March","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"339\" src=\"https://s.yimg.com/uu/api/res/1.2/eJNia005BCNXEsuyW.Qu6g--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/dbc640846da86cd22ab49eaf61ed3848\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>VANCOUVER, British Columbia, February 11, 2025</b>--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:</p>\n<ul>\n<li>45th Annual TD Cowen Health Care Conference, March 3-5</li>\n<li>KeyBanc Capital Markets Healthcare Forum, March 18-19</li>\n</ul>\n<p>Visit AbCellera's Investor Relations website for additional information.</p>\n<p><b>About <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc</b>.</p>\n<p>AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250211013862/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Inquiries </b><br/>Media: Tiffany Chiu; media@abcellera.com, +1(604)724-1242<br/>Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005<br/>Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116<br/><br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbCellera to Participate at Upcoming Investor Conferences in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbCellera to Participate at Upcoming Investor Conferences in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-12 05:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/abcellera-participate-upcoming-investor-conferences-210500935.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VANCOUVER, British Columbia, February 11, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:\n\n45th Annual TD Cowen...</p>\n\n<a href=\"https://finance.yahoo.com/news/abcellera-participate-upcoming-investor-conferences-210500935.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://finance.yahoo.com/news/abcellera-participate-upcoming-investor-conferences-210500935.html","article_id":"2510357147","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510357147","pubTimestamp":1739307900,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"VANCOUVER, British Columbia, February 11, 2025----AbCellera  today announced that the Company will participate in the following investor conferences:. 45th Annual TD Cowen Health Care Conference, March 3-5. Visit AbCellera's Investor Relations website for additional information.AbCellera  discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.Inquiries Media: Tiffany Chiu; media@abcellera.com, +1724-1242Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1559-9005Investor Relatio","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","ABCL":"AbCellera Biologics","BK4535":"淡马锡持仓"},"translate_title":"AbCellera将参加即将于3月份举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":0.9},"content_text":"VANCOUVER, British Columbia, February 11, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:\n\n45th Annual TD Cowen Health Care Conference, March 3-5\nKeyBanc Capital Markets Healthcare Forum, March 18-19\n\nVisit AbCellera's Investor Relations website for additional information.\nAbout AbCellera Biologics Inc.\nAbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250211013862/en/\nContacts\nInquiries Media: Tiffany Chiu; media@abcellera.com, +1(604)724-1242Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1}}}